Novo Nordisk A/S (NYSE:NVO) Position Increased by Advisory Resource Group

Advisory Resource Group lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 61.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,985 shares of the company’s stock after acquiring an additional 4,544 shares during the quarter. Advisory Resource Group’s holdings in Novo Nordisk A/S were worth $1,031,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S during the third quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $42,000. Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC grew its position in Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at $46,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $86.39 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. The firm has a market cap of $387.66 billion, a PE ratio of 26.26, a PEG ratio of 0.96 and a beta of 0.45. The firm’s 50 day moving average price is $91.46 and its 200 day moving average price is $111.51. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts expect that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.